WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, a biotechnology company spearheading the movement to harness the regenerative potential of target populations of stem cells inside the body, today announced that David Lucchino, Co-Founder, President and Chief Executive Officer, will provide a corporate update at the Cowen & Company 38th Annual Health Care Conference taking place March 12-14 at the Marriott Copley Place Hotel in Boston, MA.
“We look forward to presenting an update on Frequency as we move toward Phase 2 clinical studies for our lead program in hearing restoration later this year,” said David Lucchino, President, Co-founder and CEO of Frequency. “Frequency has made enormous strides over the past months in further developing and expanding our PCA Regeneration platform. The recently announced collaborations with the U.S. Army and Harvard Stem Cell Institute and separately with JDRF, highlight our advancement in muscle and type 1 diabetes, which are now a part of our ever-growing pipeline.”
Further details on the presentation are as follows:
Date: Monday, March 12
Time: 4:30 – 4:55 PM ET
Location: Private Company Presentations, MIT, 3rd Floor
ABOUT FREQUENCY THERAPEUTICS
Frequency Therapeutics develops small molecule drugs to stimulate cells in the body to reverse biological deficits and restore healthy tissue. Through the transitory activation of these cells, Frequency enables disease modification without the complexity of genetic engineering. Our breakthrough therapy uses a proprietary combination of small-molecule drugs that induce dormant progenitor cells to multiply and create new cells. Our platform technology is founded on discoveries in progenitor cell biology by Bob Langer, Sc.D. at MIT and Jeff Karp, Ph.D., at Harvard, with contributions from Xiaolei Yin, Ph.D. and other members of the Karp Lab at Harvard and Brigham & Women's Hospital. www.frequencytx.com.